<h4>Background</h4>Baseline recurrence risk increasingly guides adjuvant endocrine therapy for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (BC). This evidence concerns the gene ERBB2 and breast carcinoma.